-
Je něco špatně v tomto záznamu ?
Emetine blocks DNA replication via proteosynthesis inhibition not by targeting Okazaki fragments
D. Lukac, Z. Machacova, P. Moudry
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2018
Freely Accessible Science Journals
od 2018
PubMed Central
od 2018
ROAD: Directory of Open Access Scholarly Resources
od 2018
PubMed
36260751
DOI
10.26508/lsa.202201560
Knihovny.cz E-zdroje
- MeSH
- chromatin MeSH
- DNA genetika MeSH
- emetin * farmakologie MeSH
- jednovláknová DNA * MeSH
- replikace DNA MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
DNA synthesis of the leading and lagging strands works independently and cells tolerate single-stranded DNA generated during strand uncoupling if it is protected by RPA molecules. Natural alkaloid emetine is used as a specific inhibitor of lagging strand synthesis, uncoupling leading and lagging strand replication. Here, by analysis of lagging strand synthesis inhibitors, we show that despite emetine completely inhibiting DNA replication: it does not induce the generation of single-stranded DNA and chromatin-bound RPA32 (CB-RPA32). In line with this, emetine does not activate the replication checkpoint nor DNA damage response. Emetine is also an inhibitor of proteosynthesis and ongoing proteosynthesis is essential for the accurate replication of DNA. Mechanistically, we demonstrate that the acute block of proteosynthesis by emetine temporally precedes its effects on DNA replication. Thus, our results are consistent with the hypothesis that emetine affects DNA replication by proteosynthesis inhibition. Emetine and mild POLA1 inhibition prevent S-phase poly(ADP-ribosyl)ation. Collectively, our study reveals that emetine is not a specific lagging strand synthesis inhibitor with implications for its use in molecular biology.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033295
- 003
- CZ-PrNML
- 005
- 20230131151857.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.26508/lsa.202201560 $2 doi
- 035 __
- $a (PubMed)36260751
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lukac, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 245 10
- $a Emetine blocks DNA replication via proteosynthesis inhibition not by targeting Okazaki fragments / $c D. Lukac, Z. Machacova, P. Moudry
- 520 9_
- $a DNA synthesis of the leading and lagging strands works independently and cells tolerate single-stranded DNA generated during strand uncoupling if it is protected by RPA molecules. Natural alkaloid emetine is used as a specific inhibitor of lagging strand synthesis, uncoupling leading and lagging strand replication. Here, by analysis of lagging strand synthesis inhibitors, we show that despite emetine completely inhibiting DNA replication: it does not induce the generation of single-stranded DNA and chromatin-bound RPA32 (CB-RPA32). In line with this, emetine does not activate the replication checkpoint nor DNA damage response. Emetine is also an inhibitor of proteosynthesis and ongoing proteosynthesis is essential for the accurate replication of DNA. Mechanistically, we demonstrate that the acute block of proteosynthesis by emetine temporally precedes its effects on DNA replication. Thus, our results are consistent with the hypothesis that emetine affects DNA replication by proteosynthesis inhibition. Emetine and mild POLA1 inhibition prevent S-phase poly(ADP-ribosyl)ation. Collectively, our study reveals that emetine is not a specific lagging strand synthesis inhibitor with implications for its use in molecular biology.
- 650 12
- $a emetin $x farmakologie $7 D004640
- 650 12
- $a jednovláknová DNA $7 D004277
- 650 _2
- $a DNA $x genetika $7 D004247
- 650 _2
- $a replikace DNA $7 D004261
- 650 _2
- $a chromatin $7 D002843
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Machacova, Zuzana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Moudry, Pavel $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic pavel.moudry@upol.cz $1 https://orcid.org/000000021479007X
- 773 0_
- $w MED00197314 $t Life science alliance $x 2575-1077 $g Roč. 5, č. 12 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36260751 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151853 $b ABA008
- 999 __
- $a ok $b bmc $g 1891842 $s 1184630
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 5 $c 12 $e 20220909 $i 2575-1077 $m Life science alliance $n Life sci. alliance $x MED00197314
- LZP __
- $a Pubmed-20230120